on IPSEN (EPA:IPN)
Promising results for Cabometyx in advanced neuroendocrine tumors
Ipsen has announced final results from the Phase III CABINET trial, showing the efficacy of Cabometyx® (cabozantinib) in advanced neuroendocrine tumors. The data show a significant reduction in the risk of disease progression or death compared to placebo.
The study, presented at ESMO Congress 2024, demonstrates statistical and clinical benefits, with a 77% risk reduction for pancreatic neuroendocrine tumors and 62% for extrapancreatic neuroendocrine tumors. Median follow-up shows notable progression-free survival for patients treated with Cabometyx.
In response, Ipsen filed an application for an extension of indication with the European Medicines Agency. Given the limited treatment options for these tumors, these results could represent a significant advance.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all IPSEN news